Literature DB >> 31175218

Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.

Clare Stokes1, Sumanta Garai1, Abhijit R Kulkarni1, Lucas N Cantwell1, Colleen M Noviello1, Ryan E Hibbs1, Nicole A Horenstein1, Khalil A Abboud1, Ganesh A Thakur1, Roger L Papke2.   

Abstract

Homomeric α7 nicotinic acetylcholine receptors (nAChR) have an intrinsically low probability of opening that can be overcome by α7-selective positive allosteric modulators (PAMs), which bind at a site involving the second transmembrane domain (TM2). Mutation of a methionine that is unique to α7 at the 15' position of TM2 to leucine, the residue in most other nAChR subunits, largely eliminates the activity of such PAMs. We tested the effect of the reverse mutation (L15'M) in heteromeric nAChR receptors containing α4 and β2, which are the nAChR subunits that are most abundant in the brain. Receptors containing these mutations were found to be strongly potentiated by the α7 PAM 3a,4,5,9b-tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS) but insensitive to the alternative PAM 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea. The presence of the mutation in the β2 subunit was necessary and sufficient for TQS sensitivity. The primary effect of the mutation in the α4 subunit was to reduce responses to acetylcholine applied alone. Sensitivity to TQS required only a single mutant β subunit, regardless of the position of the mutant β subunit within the pentameric complex. Similar results were obtained when β2L15'M was coexpressed with α2 or α3 and when the L15'M mutation was placed in β4 and coexpressed with α2, α3, or α4. Functional receptors were not observed when β1L15'M subunits were coexpressed with other muscle nAChR subunits. The unique structure-activity relationship of PAMs and the α4β2L15'M receptor compared with α7 and the availability of high-resolution α4β2 structures may provide new insights into the fundamental mechanisms of nAChR allosteric potentiation. SIGNIFICANCE STATEMENT: Heteromeric neuronal nAChRs have a relatively high initial probability of channel activation compared to receptors that are homomers of α7 subunits but are insensitive to PAMs, which greatly increase the open probability of α7 receptors. These features of heteromeric nAChR can be reversed by mutation of a single residue present in all neuronal heteromeric nAChR subunits to the sequence found in α7. Specifically, the mutation of the TM2 15' leucine to methionine in α subunits reduces heteromeric receptor channel activation, while the same mutation in neuronal β subunits allows heteromeric receptors to respond to select α7 PAMs. The results indicate a key role for this residue in the functional differences in the two main classes of neuronal nAChRs.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31175218      PMCID: PMC6658922          DOI: 10.1124/jpet.119.259499

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  71 in total

1.  A study of the desensitization produced by acetylcholine at the motor end-plate.

Authors:  B KATZ; S THESLEFF
Journal:  J Physiol       Date:  1957-08-29       Impact factor: 5.182

Review 2.  Selective alpha7 nicotinic acetylcholine receptor ligands.

Authors:  Anatoly Mazurov; Terry Hauser; Craig H Miller
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 3.  Cholinergic control of inflammation.

Authors:  M Rosas-Ballina; K J Tracey
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

4.  Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Mol Pharmacol       Date:  2011-09-01       Impact factor: 4.436

5.  B-973, a novel piperazine positive allosteric modulator of the α7 nicotinic acetylcholine receptor.

Authors:  Debra J Post-Munson; Rick L Pieschl; Thaddeus F Molski; John D Graef; Adam W Hendricson; Ronald J Knox; Ivar M McDonald; Richard E Olson; John E Macor; Michael R Weed; Linda J Bristow; Laszlo Kiss; Michael K Ahlijanian; James Herrington
Journal:  Eur J Pharmacol       Date:  2017-01-26       Impact factor: 4.432

6.  Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors.

Authors:  Vladimir V Uteshev; Edwin M Meyer; Roger L Papke
Journal:  Brain Res       Date:  2002-09-06       Impact factor: 3.252

Review 7.  Merging old and new perspectives on nicotinic acetylcholine receptors.

Authors:  Roger L Papke
Journal:  Biochem Pharmacol       Date:  2014-01-31       Impact factor: 5.858

8.  Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist.

Authors:  Shu-Xing Li; Sun Huang; Nina Bren; Kaori Noridomi; Cosma D Dellisanti; Steven M Sine; Lin Chen
Journal:  Nat Neurosci       Date:  2011-09-11       Impact factor: 24.884

9.  The activity of GAT107, an allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), is regulated by aromatic amino acids that span the subunit interface.

Authors:  Roger L Papke; Nicole A Horenstein; Abhijit R Kulkarni; Clare Stokes; Lu W Corrie; Cheol-Young Maeng; Ganesh A Thakur
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

Review 10.  New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs.

Authors:  Deniz Bagdas; Mine S Gurun; Pamela Flood; Roger L Papke; M Imad Damaj
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

View more
  4 in total

1.  Allosterically Potentiated α7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium.

Authors:  Douglas R Miller; Habibeh Khoshbouei; Sumanta Garai; Lucas N Cantwell; Clare Stokes; Ganesh Thakur; Roger L Papke
Journal:  Mol Pharmacol       Date:  2020-10-05       Impact factor: 4.436

2.  Stable desensitization of α7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site.

Authors:  Maria Chiara Pismataro; Nicole A Horenstein; Clare Stokes; Clelia Dallanoce; Ganesh A Thakur; Roger L Papke
Journal:  Eur J Pharmacol       Date:  2021-05-15       Impact factor: 5.195

3.  The Allosteric Activation of α7 nAChR by α-Conotoxin MrIC Is Modified by Mutations at the Vestibular Site.

Authors:  Alican Gulsevin; Roger L Papke; Clare Stokes; Hue N T Tran; Aihua H Jin; Irina Vetter; Jens Meiler
Journal:  Toxins (Basel)       Date:  2021-08-10       Impact factor: 4.546

Review 4.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.